OpenNashPodcasts

Topic

Genentech

11 facts from 5 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.

1980

In 1980 Genentech and Eli Lilly announced a partnership to produce human insulin using recombinant DNA, the first genetically engineered drug.

“in 1980, Genentech and Eli Lilly, as their partner, changed everything with recombinant DNA and genetic engineering of drugs.”

Acquired · Novo Nordisk (Ozempic), 1:11:20

1980

Genentech raised $35 million in its 1980 initial public offering, which was considered an enormous amount at the time.

“Genentech, when it went public in 1980, 10 years earlier, it raised $35 million”

Matthew Pech · Episode #2: Geron, 0:14:01

1995-2009

Sue Desmond-Hellmann worked at Genentech from 1995 to 2009, a period the host describes as its glory days as a developer of cancer drugs.

“She made her name in the biopharmaceutical industry at Genentech from 1995 to 2009, the glory days when it became the world's most important developer of new cancer drugs.”

Luke Timmerman · Ep95: Sue Desmond-Hellmann on Becoming a Biotech Leader, 0:00:01

Undated

Genentech's R&D head Art Levinson believed in leaving a job open rather than hiring a 'B minus', which made rapid growth harder.

“Art had this philosophy that if you couldn't find the right person for the job, you should just leave it open.”

Sue Desmond-Hellmann · Ep95: Sue Desmond-Hellmann on Becoming a Biotech Leader, 0:48:54

Undated

Recursion signed a collaboration with Roche and Genentech lasting more than a decade, covering neuroscience and one oncology indication.

“In December, almost exactly a year ago, December last year, we signed a huge collaboration with Rosh and Genentech to deploy our technology in partnership with them for more than a decade”

Chris Gibson · AI & Computational Biology With Recursion's Chris Gibson, Ph.D., 0:36:05

Episodes